| |
| |
|
| Insider
Information: |
Thompson Peter A |
| Relationship: |
Director |
| City: |
Bellevue |
| State: |
WA |
| |
|
| Insider
Summary: |
|
|
|
|
Companies Owned : |
12 |
|
| Direct
Shares |
385,419 |
|
|
Indirect Shares
|
41,741,947 |
|
|
| Direct
Value |
$0 |
|
|
|
Indirect Value
|
$304,920,542 |
|
|
| Total
Shares |
42,127,366 |
|
|
| Total
Value |
$304,920,542 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
|
Total
Filings :
|
2
|
4
|
|
Stock
price went up :
|
1
|
2
|
| Stock
price went down : |
1
|
2
|
| |
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
| Percentage
Gain/Loss : |
 19.0%
|
340.8%
|
| |
|
|
|
|
|
Holdings
:
| Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold  |
 |
Trubion Pharmaceuticals, Inc |
TRBN |
President and CEO, Dir... |
2009-05-22 |
385,419 |
2009-05-22 |
1,000 |
Premium* |
|
|
Sierra Oncology Inc |
SRRA |
Director |
2015-07-21 |
0 |
2015-07-21 |
1,989,949 |
Premium* |
|
|
Adaptimmune Therapeutics PLC |
ADAP |
Director |
|
0 |
2018-06-06 |
4,901,310 |
Premium* |
|
|
Corvus Pharmaceuticals, Inc. |
CRVS |
Director, 10% Owner |
2016-03-29 |
0 |
2021-09-20 |
6,943,654 |
Premium* |
|
|
Alpine Immune Sciences Inc |
ALPN |
Director |
2017-07-24 |
0 |
2024-01-11 |
2,680,496 |
Premium* |
|
|
Synthorx, Inc. |
THOR |
Director, 10% Owner |
2018-12-11 |
0 |
2020-01-23 |
0 |
Premium* |
|
|
Prevail Therapeutics Inc. |
PRVL |
Director, 10% Owner |
|
0 |
2021-01-22 |
0 |
Premium* |
|
|
Pmv Pharmaceuticals, Inc. |
PMVP |
Director, 10% Owner |
2020-09-29 |
0 |
2020-09-29 |
114,039 |
Premium* |
|
|
Silverback Therapeutics, Inc. |
SBTX |
Director |
|
0 |
2023-08-29 |
9,240,887 |
Premium* |
|
|
Decibel Therapeutics, Inc. |
DBTX |
Director, 10% Owner |
2021-02-17 |
0 |
2021-02-17 |
883,418 |
Premium* |
|
|
Edgewise Therapeutics, Inc. |
EWTX |
Director, 10% Owner |
|
0 |
2024-01-23 |
14,756,096 |
Premium* |
|
|
Janux Therapeutics, Inc. |
JANX |
Director |
2021-12-16 |
0 |
2021-12-29 |
231,098 |
Premium* |
|
|
|
|
|
|
|
|
|
|
|
Records found :
71 |
Free Registration Required For Full Results. Limit: 25
|
 |
Download |
Page 3 of 3
|
| Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
| TRBN |
Trubion Pharmaceuticals, ... |
President and CEO |
• • – |
2006-10-18 |
4 |
B |
$13.00 |
$13,000 |
I/I |
1,000 |
255,032 |
2.58 |
- |
|
| CRVS |
Corvus Pharmaceuticals, I... |
Director |
– • • |
2016-05-20 |
4 |
B |
$13.09 |
$61,732 |
I/I |
4,716 |
5,269,966 |
2.25 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2018-06-01 |
4 |
S |
$13.49 |
$674,500 |
I/I |
(50,000) |
4,920,010 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2018-06-06 |
4 |
S |
$13.49 |
$21,584 |
I/I |
(1,600) |
4,901,310 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2018-05-14 |
4 |
S |
$13.50 |
$139,050 |
I/I |
(10,300) |
5,091,010 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2018-05-30 |
4 |
S |
$13.52 |
$1,635,920 |
I/I |
(121,000) |
4,970,010 |
0 |
- |
|
| ADAP |
Adaptimmune Therapeutics ... |
Director |
– • – |
2018-06-04 |
4 |
S |
$13.57 |
$232,047 |
I/I |
(17,100) |
4,902,910 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • • |
2020-12-28 |
4 |
S |
$14.25 |
$8,550,000 |
I/I |
(600,000) |
3,070,955 |
0 |
% |
|
| CRVS |
Corvus Pharmaceuticals, I... |
Director |
– • • |
2016-03-29 |
4 |
B |
$15.00 |
$8,250,000 |
I/I |
550,000 |
5,258,450 |
2.25 |
- |
|
| EWTX |
Edgewise Therapeutics, In... |
Director |
– • • |
2021-03-30 |
4 |
B |
$16.00 |
$5,750,000 |
I/I |
359,375 |
13,359,456 |
2.25 |
- |
|
| SRRA |
Sierra Oncology Inc |
Director |
– • – |
2015-07-21 |
4 |
B |
$17.00 |
$2,975,000 |
I/I |
175,000 |
1,989,949 |
2.1 |
- |
|
| PRVL |
Prevail Therapeutics Inc. |
Director |
– • • |
2019-06-24 |
4 |
B |
$17.00 |
$14,999,984 |
I/I |
882,352 |
13,822,463 |
2.25 |
- |
|
| PMVP |
Pmv Pharmaceuticals, Inc. |
Director |
– • • |
2020-09-25 |
4 |
B |
$18.00 |
$17,100,000 |
I/I |
950,000 |
475,000 |
2.25 |
- |
|
| DBTX |
Decibel Therapeutics, Inc... |
Director |
– • • |
2021-02-17 |
4 |
B |
$18.00 |
$29,999,988 |
I/I |
1,666,666 |
883,418 |
2.25 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • – |
2023-12-28 |
4 |
S |
$18.32 |
$25,049,034 |
I/I |
(1,364,849) |
264,315 |
0 |
% |
|
| JANX |
Janux Therapeutics, Inc. |
Director |
– • – |
2021-12-21 |
4 |
S |
$19.00 |
$2,268,600 |
I/I |
(119,400) |
234,798 |
0 |
- |
|
| JANX |
Janux Therapeutics, Inc. |
Director |
– • – |
2021-12-16 |
4 |
S |
$19.07 |
$7,500,231 |
I/I |
(393,300) |
245,898 |
0 |
- |
|
| ALPN |
Alpine Immune Sciences In... |
Director |
– • – |
2023-12-27 |
4 |
S |
$19.96 |
$3,622,700 |
I/I |
(181,498) |
406,609 |
0 |
% |
|
| JANX |
Janux Therapeutics, Inc. |
Director |
– • – |
2021-12-29 |
4 |
S |
$20.30 |
$820,120 |
I/I |
(40,400) |
231,098 |
0 |
- |
|
| SBTX |
Silverback Therapeutics, ... |
Director |
– • • |
2020-12-08 |
4 |
B |
$21.00 |
$25,000,017 |
I/I |
1,190,477 |
952,377 |
2.25 |
- |
|
| THOR |
Synthorx, Inc. |
Director |
– • • |
2020-01-23 |
4 |
D |
$68.00 |
$361,512,140 |
I/I |
(5,316,355) |
0 |
0 |
- |
|
71 Records found
|
|
Page 3 of 3 |
| |
Free Registration Required For Full Results. Limit: 25
|
|
| |
Transaction Code Key: |
Ownership Code Key |
| |
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
| |
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
| |
IO |
- Initital Ownership |
D |
- Disposed |
| |
|
|
|
|
|
